OBJECTIVETo evaluate the effects of combined treatment of hormone therapy with strontium-89 for pain from bone metastases in patients with prostate cancer.

METHODSSixteen patients with metastasis prostate cancer received hormone therapy with strontium-89 chloride (89Sr), and 4 of them received radiotherapy.

RESULTSThe pain was relieved. Relief occurred in 75.6% of the patients for 3 months, 80.5% for 6 months and 63.4% for 9 months.

CONCLUSIONHormone therapy enhances the effect of 89Sr without obvious toxicity. The combined treatment not only significantly raises pain palliation, prolongs pain-free survival, but improves the patients life quality.

Aged ; Aged, 80 and over ; Androgen Antagonists ; therapeutic use ; Bone Neoplasms ; physiopathology ; secondary ; therapy ; Combined Modality Therapy ; Humans ; Male ; Middle Aged ; Pain, Intractable ; therapy ; Prostatic Neoplasms ; therapy ; Strontium ; therapeutic use